AMT-253 for advanced solid tumors after standard treatments
Part of Cancer clinical trials.
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent and follow study visits
- Have advanced solid tumor cancer that has progressed after at least one treatment, and no suitable standard options left
- Have at least one measurable tumor spot that can be tracked on scans
- Be able to do daily activities with an ECOG score of 0–1 (generally fully active to some limits)
- Have adequate blood/organ function and at least 3 months of expected life
- Have tumor tissue available from a past sample or a new biopsy for study testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
This Phase 1/2 trial tests XTX301, a study treatment, in people with advanced solid tumors (cancers) that have already been treated and are not controlled by standard options. It may help if your cancer matches one of the study groups and you meet safety and test-tissue requirements.
This Phase 1 trial tests a new medicine (HG381) in people with advanced solid tumors to see how safe it is and how it works in the body. It may help if standard treatments have already stopped working or aren’t possible for you.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
This study tests an experimental drug AMT-253 in people with advanced solid tumors (like melanoma) that have progressed despite prior treatment. The goal is to see if the drug can help shrink or slow the cancer.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.